Severity
Critical
FDA Drug recall · Reported January 10, 2018
SUPERPOTENT: Weight variations resulting in tablets that are sub and super potent
Pfizer Inc. recalled diphenoxylate hydrochloride and atropine sulfate tablets, USP, 2.5 mg/0.025 mg, a) 100-c… - a critical-severity action.
diphenoxylate hydrochloride and atropine sulfate tablets, USP, 2.5 mg/0.025 mg, a) 100-c… was recalled by Pfizer Inc. in January 10, 2018. Reason: SUPERPOTENT: Weight variations resulting in tablets that are sub and super potent. Check the official notice for the remedy. Verify recall #D-0150-2018 with the FDA Drug before acting.
The recall
Pfizer Inc. issued this critical-severity FDA Drug recall-SUPERPOTENT: Weight variations resulting in tablets that are sub and super potent.
Sourced from official FDA Drug enforcement records. Verify recall #D-0150-2018 with the agency before acting. Full product description, hazard, remedy, and related recalls are below.
This FDA Drug action (record #D-0150-2018) was formally reported on January 10, 2018, with the manufacturer initiating the action on October 20, 2017. It is classified under Critical severity (Class I), with a current status of Terminated. Pfizer Inc. is listed as the recalling firm, operating out of New York, NY. Federal records list the affected scope as 183437 bottles.
The documented reason for this recall is: SUPERPOTENT: Weight variations resulting in tablets that are sub and super potent Distribution data in the federal record shows the product reached: Nationwide in the USA. Distribution scope directly affects the consumer exposure window and determines whether a recall remains regional or escalates into a nationwide advisory.
Within the same product category the archive holds 6 closely related recalls - clustering in a narrow category often points to a systemic quality-control or supplier issue rather than a one-off defect. Always verify the recall number against the official agency record before acting.
Where this recall sits in its category - 3,731 children & baby products recalls on record
Of 101,704 recalls in the database, 24,878 are high severity, 72,426 moderate, and 4,400 low. This recall is classified high severity.
Counts reflect market size and reporting activity, not inherent danger, we do not rank products by risk from raw recall volume.
Severity
Critical
Affected scope
183437 bottles
Related Recalls
6
0 from same agency
diphenoxylate hydrochloride and atropine sulfate tablets, USP, 2.5 mg/0.025 mg, a) 100-count bottle (NDC 59762-1061-1), b) 1000-count bottle (NDC 59762-1061-2), Rx Only, Distributed by: Greenstone LLC. Peapack, NJ 07977
SUPERPOTENT: Weight variations resulting in tablets that are sub and super potent
| Attribute | Value |
|---|---|
| Agency | U.S. Food and Drug Administration |
| Severity class | Critical (Class I) |
| Status | Terminated |
| Recall number | D-0150-2018 |
| Date reported | January 10, 2018 |
| Date initiated | October 20, 2017 |
| Recalling firm | Pfizer Inc. |
| Firm location | New York, NY |
| Affected scope | 183437 bottles |
| Distribution | Nationwide in the USA |
Profile values are sourced directly from the official FDA Drug enforcement record. Source: U.S. Food and Drug Administration.
What to do with this recall
Match your product against the recall record, then act on the agency remedy.
This page summarizes the official FDA Drug record for research and awareness; it is not legal, medical, or safety advice. Verify with the issuing agency before acting.
Other recalls in the same product category, useful for spotting patterns across the same defect class or manufacturer.
Xishentang Dongguan Trading Co, Ltd., dba Pretty-Life, of China · 2026-07-02
Diamond Wipes International, Inc. of Chino, California · 2026-07-02
· 2026-07-02
· 2026-07-02
Sanven Technology Ltd., dba Vevor, of Rancho Cucamonga, California · 2026-07-02
Compare this recall with AMASKY Nursing Pillows Recalled Due to Risk of Serious Inju… →
Every figure on PlainRecalls is rendered directly from official FDA, CPSC and NHTSA recall records, no number is typed in by an editor. This recall: FDA Drug, reported January 10, 2018. Severity classes follow each agency's own taxonomy (FDA Class I/II/III; CPSC and NHTSA by hazard type), and related-recall context is computed across the full archive. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of July 2026.